There wouldn’t be many who think Bristol-Myers Squibb Company’s (NYSE:BMY) price-to-sales (or “P/S”) ratio of 2.5x is worth a mention when the median P/S for the Pharmaceuticals industry in the United States is similar at about 2.9x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.
See our latest analysis for Bristol-Myers Squibb
How Has Bristol-Myers Squibb Performed Recently?
With revenue growth that’s inferior to most other companies of late, Bristol-Myers Squibb has been relatively sluggish. Perhaps the market is expecting future revenue performance to lift, which has kept the P/S from declining. If not, then existing shareholders may be a little nervous about the viability of the share price.
If you’d like to see what analysts are forecasting going forward, you should check out…
